James Waldron

Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell therapies into the clinic.

Check out Fierce Biotech's conference's kickoff coverage here and for full lowdown from Day 2 here Check out all the latest news below...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension drug, Keros Therapeutics has now pulled the plug on the study entirely.

OS Therapies' HER2-focused immunotherapy prevented patients' lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial.

Servier is extending its pact with Google Cloud as the French biopharma points to 60 examples of how generative artificial intelligence could improve its drug development processes.

One of the biggest stories of last year was Lykos Therapeutics' failure to get its MDMA candidate over the finish line for post-traumatic stress

Chinese biotechs InnoCare Pharma and KeyMed Biosciences have sold the international rights to a clinical-stage bispecific antibody to a new company created by RTW Investments for $17.5 million in near-term cash.

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.

A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing deals.

Tris Pharma has pointed to a phase 3 win for its pain relief drug as demonstrating the candidate's potential to help resolve the opioid crisis.